IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2246 
Small font sizeDefault font sizeIncrease font size
Read this article

 


    Article Cited by others

SHORT COMMUNICATION

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes

Mahajan Rajiv

Year : 2009| Volume: 41| Issue : 4 | Page no: 197-198

   This article has been cited by
 
1 Antihyperglycemic, Antihyperlipidemic and Cardioprotective Profile of Bromocriptine, Glibenclamide and Metformin Combination in Dexamethasone-induced Hyperglycemic Rats
Adejuwon Adewale Adeneye,Joseph Abayomi Olagunju
Pharmacologia. 2012; 3(12): 665
[Pubmed]  [Google Scholar] [DOI]
2 Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study
European Journal of Pharmaceutics and Biopharmaceutics. 2011;
[HTML Full text]  [Google Scholar] [DOI]
3 Bromocriptine mesylate for glycemic management in type 2 diabetes mellitus
Kerr, J.L., Timpe, E.M., Petkewicz, K.A.
Annals of Pharmacotherapy. 2010; 44(11): 1777-1785
[Pubmed]  [Google Scholar]
4 A systematic account of pathogenesis, diagnosis and pharmacotherapy of metabolic syndrome: Things we need to know
Mahajan, R., Gupta, K., Kapoor, V.
International Journal of Pharmacology. 2010; 6(4): 430-437
[Pubmed]  [Google Scholar]
5 A Systematic Account of Pathogenesis, Diagnosis and Pharmacotherapy of Metabolic Syndrome: Things We Need to Know
R. Mahajan, K. Gupta, V. Kapoor
International Journal of Pharmacology. 2010; 6(4): 338
[HTML Full text]  [Google Scholar] [DOI]

 

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow